GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2006

Cato to Provide Strategic Drug Development Services for Jenken in Exchange for Equity

  • Jenken Biosciences signed a services agreement valued at up to $2 million with Cato Research, a global CRO, and Cato BioVentures, its venture capital affiliate. Under Cato BioVentures' equity-based compensation model, Cato Research will provide strategic drug development services and regulatory advice related to the clinical development of JKB-122, Jenken's lead drug candidate for the treatment or prevention of liver damage associated with hepatitis C and other diseases associated with organ inflammation.

    "Cato BioVentures and Cato Research are committed to working with early- stage companies like Jenken. When we partner early, as we have here, we can make a positive difference in the overall development of promising drug candidates like Jenken's JKB-122, a compound with exciting potential to impact the treatment of hepatitis C-related inflammatory liver disease," said Shawn K. Singh, managing principal of Cato BioVentures. "This strategic development agreement is flexible, broad-based and reflects a tight fit between our venture program and Jenken's innovative drug repurposing model."



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?